| Literature DB >> 17113187 |
Akmal S Hassan1, Ursula Kaelin, Lasse Roger Braathen, Nikhil Yawalkar.
Abstract
Treatment of widespread moderate to severe atopic eczema remains a challenge. The therapeutic efficacy and modifications of the immune response during treatment of atopic eczema with efalizumab are so far unknown. We hereby report the clinical findings and characterize the inflammatory infiltrate during treatment of severe recalcitrant atopic eczema with efalizumab.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17113187 DOI： 10.1016/j.jaad.2006.08.025
Source DB: PubMed Journal: J Am Acad Dermatol ISSN： 0190-9622 Impact factor: 11.527